Macomics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 22

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $14.8M

  • Investors
  • 6

Macomics General Information

Description

Developer of precision medicines designed to modulate macrophages for the treatment of cancer. The company's medicines target the immunosuppressive tumor microenvironment, which exploits disease-specific macrophage biology to harness the power of the immune system, enabling medical practitioners and pharma companies to give clinical benefits to many more patients suffering from cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • The University of Edinburgh, Campus Service Centre
  • Roslin Innovation Centre, Easter Bush Campus
  • Edinburgh EH25 9RG
  • Scotland, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • The University of Edinburgh, Campus Service Centre
  • Roslin Innovation Centre, Easter Bush Campus
  • Edinburgh EH25 9RG
  • Scotland, United Kingdom

Macomics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Macomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 21-Oct-2026 $14.8M Completed Generating Revenue
5. Later Stage VC 01-Mar-2023 Completed Pre-Clinical Trials
4. Seed Round 21-Jul-2021 Completed Pre-Clinical Trials
3. Seed Round 14-Jul-2020 Completed Pre-Clinical Trials
2. Accelerator/Incubator Completed Startup
1. University Spin-Out 06-Nov-2018 Completed Startup
To view Macomics’s complete valuation and funding history, request access »

Macomics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series 4 Seed
Series 3 Seed
Series 2 Seed 340,767 $0.001326 $7.07 $7.07 1x $7.07 8.84%
Series 1 Seed 255,575 $0.001326 $7.07 $7.07 1x $7.07 6.63%
To view Macomics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Macomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of precision medicines designed to modulate macrophages for the treatment of cancer. The company's medicines t
Drug Discovery
Edinburgh, United Kingdom
22 As of 2025

Madison, WI
 

Cambridge, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Macomics Competitors (57)

One of Macomics’s 57 competitors is Centrose, a Venture Capital-Backed company based in Madison, WI.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Centrose Venture Capital-Backed Madison, WI
Mestag Therapeutics Venture Capital-Backed Cambridge, United Kingdom
NeoPhore Venture Capital-Backed Altrincham, United Kingdom
Aronora Venture Capital-Backed Portland, OR
Meditope Biosciences Formerly VC-backed Pasadena, CA
You’re viewing 5 of 57 competitors. Get the full list »

Macomics Patents

Macomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202415693-D0 Genetically-engineered cells Inactive 24-Oct-2024
WO-2026087790-A1 Genetically-engineered cells Pending 24-Oct-2024
GB-202314087-D0 Biomarker for cancer Inactive 14-Sep-2023
WO-2025056812-A1 Biomarker for cancer Inactive 14-Sep-2023
GB-202314086-D0 Compositions and method for modulation of macrophage activity Inactive 14-Sep-2023
To view Macomics’s complete patent history, request access »

Macomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Macomics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
LifeLink Ventures Venture Capital Minority
Old College Capital Venture Capital Minority
Epidarex Capital Venture Capital Minority
Scottish Enterprise Growth/Expansion Minority
The University of Edinburgh University Minority
You’re viewing 5 of 6 investors. Get the full list »

Macomics FAQs

  • When was Macomics founded?

    Macomics was founded in 2018.

  • Where is Macomics headquartered?

    Macomics is headquartered in Edinburgh, United Kingdom.

  • What is the size of Macomics?

    Macomics has 22 total employees.

  • What industry is Macomics in?

    Macomics’s primary industry is Drug Discovery.

  • Is Macomics a private or public company?

    Macomics is a Private company.

  • What is the current valuation of Macomics?

    The current valuation of Macomics is .

  • What is Macomics’s current revenue?

    The current revenue for Macomics is .

  • How much funding has Macomics raised over time?

    Macomics has raised $24.6M.

  • Who are Macomics’s investors?

    LifeLink Ventures, Old College Capital, Epidarex Capital, Scottish Enterprise, and The University of Edinburgh are 5 of 6 investors who have invested in Macomics.

  • Who are Macomics’s competitors?

    Centrose, Mestag Therapeutics, NeoPhore, Aronora, and Meditope Biosciences are some of the 57 competitors of Macomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process